GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (OTCPK:SRNE) » Definitions » FCF Margin %

Sorrento Therapeutics (Sorrento Therapeutics) FCF Margin % : -371.37% (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Sorrento Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sorrento Therapeutics's Free Cash Flow for the three months ended in Jun. 2023 was $-55.80 Mil. Sorrento Therapeutics's Revenue for the three months ended in Jun. 2023 was $15.03 Mil. Therefore, Sorrento Therapeutics's FCF Margin % for the quarter that ended in Jun. 2023 was -371.37%.

As of today, Sorrento Therapeutics's current FCF Yield % is -2,205.80%.

The historical rank and industry rank for Sorrento Therapeutics's FCF Margin % or its related term are showing as below:

SRNE' s FCF Margin % Range Over the Past 10 Years
Min: -3786.96   Med: -583.49   Max: -72.54
Current: -378.42


During the past 13 years, the highest FCF Margin % of Sorrento Therapeutics was -72.54%. The lowest was -3786.96%. And the median was -583.49%.

SRNE's FCF Margin % is ranked worse than
62.79% of 1032 companies
in the Biotechnology industry
Industry Median: -148.935 vs SRNE: -378.42


Sorrento Therapeutics FCF Margin % Historical Data

The historical data trend for Sorrento Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics FCF Margin % Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -580.20 -586.78 -415.31 -549.47 -489.37

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -730.24 -373.60 -467.24 -304.87 -371.37

Competitive Comparison of Sorrento Therapeutics's FCF Margin %

For the Biotechnology subindustry, Sorrento Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's FCF Margin % falls into.



Sorrento Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sorrento Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-307.514/62.839
=-489.37 %

Sorrento Therapeutics's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-55.799/15.025
=-371.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sorrento Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (Sorrento Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Executives
Henry Ji director, officer: See Remarks 5370 RUETTE DE MER, SAN DIEGO CA 92130
Tammy Reilly director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Kim Janda director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Dorman Followwill director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Najjam Asghar officer: Chief Financial Officer C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Robin L Smith director C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Edgar Lee director C/O OAKTREE CAPITAL MANAGEMENT, L.P., 333 SOUTH GRAND AVE, 28TH FLOOR, LOS ANGELES CA 90071
Jerome B Zeldis officer: See Remarks 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Jaisim Shah director C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
David Lemus director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Abg Management Ltd 10 percent owner UNIT 3002-04,30TH FLOOR,GLOUCESTER TOWER, THE LANDMARK,15 QUEEN'S ROAD CENTRAL, HONG KONG K3 000000
Jiong Shao officer: Chief Financial Officer SUITE 1003-1004, 10/F, ICBC TOWER, THREE GARDEN ROAD, CENTRAL, HONG KONG F4 000000
George K Ng officer: See Remarks C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121

Sorrento Therapeutics (Sorrento Therapeutics) Headlines

From GuruFocus